Trial Profile
A Randomized, Pilot Estimation Study to Compare the Safety and Efficacy of Raltegravir+TDF+3TC Versus TDF+3TC+EFV in HBV/HIV Co-infected Patients.
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Raltegravir (Primary) ; Efavirenz; Lamivudine; Tenofovir
- Indications Hepatitis B; HIV-1 infections
- Focus Adverse reactions
- 23 Mar 2011 New trial record